Celldex Therapeutics (CLDX) said Wednesday that the first patient has been dosed in the company's phase 1a study of CDX-622, a potential inflammatory disease treatment, in healthy volunteers.
The drug is an antibody that targets two complementary pathways that drive inflammatory diseases by neutralizing thymic stromal lymphopoietin and depleting mast cells, the company said.
The phase 1a study aims to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses and multiple ascending doses of CDX-622 in up to 56 healthy participants, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。